CDRH Announces Implementation of Office of Product Evaluation and Quality
This week CDRH officially launched the Office of Product Evaluation and Quality (OPEQ) as part of its reorganization, an effort to “adapt to future organizational, regulatory and scientific needs” that was announced in March.
OPEQ will integrate the premarket and postmarket program functions along products lines to help CDRH optimize decision making across the product lifecycle. This new, team-based structure consolidates and integrates current parts of product review, quality, surveillance and enforcement.
“OPEQ implementation is a key step in the Center’s reorganization that will help us both modernize business processes and even better fulfill our mission of ensuring patients and health care providers have continued access to safe, effective, and high-quality medical devices,” FDA stated in an agency release.
Related Articles
-
The center will start phasing in efficiencies on March 18.
-
Bringing design and quality assurance processes together earlier in the device development process can reduce costs and nonconformances, while improving outcomes.
-
Inspecting for quality after a process is completed is reactive and outdated. Instead, the future lies in predicting quality and quality issues. For medical device manufacturers, the advantages in predictive quality are so great they simply cannot be ignored.
-
On May 16-17, device developers, regulatory affairs and regulatory intelligence professionals will come together in Washington, DC, for two days of education, discussion and networking to share strategies and best practices on navigating current and on the horizon regulatory requirements.
